These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 20642495

  • 1. Calcineurin inhibitor sparing regimens using m-target of rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation?
    Zeier M, Van Der Giet M.
    Transpl Int; 2011 Jan; 24(1):30-42. PubMed ID: 20642495
    [Abstract] [Full Text] [Related]

  • 2. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study.
    Holdaas H, Rostaing L, Serón D, Cole E, Chapman J, Fellstrøm B, Strom EH, Jardine A, Midtvedt K, Machein U, Ulbricht B, Karpov A, O'Connell PJ, ASCERTAIN Investigators.
    Transplantation; 2011 Aug 27; 92(4):410-8. PubMed ID: 21697773
    [Abstract] [Full Text] [Related]

  • 3. Clinical insights for cancer outcomes in renal transplant patients.
    Alberú J.
    Transplant Proc; 2010 Nov 27; 42(9 Suppl):S36-40. PubMed ID: 21095450
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Everolimus in clinical practice--renal transplantation.
    Pascual J.
    Nephrol Dial Transplant; 2006 Jul 27; 21 Suppl 3():iii18-23. PubMed ID: 16815852
    [Abstract] [Full Text] [Related]

  • 11. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial.
    Gullestad L, Iversen M, Mortensen SA, Eiskjaer H, Riise GC, Mared L, Bjørtuft O, Ekmehag B, Jansson K, Simonsen S, Gude E, Rundqvist B, Fagertun HE, Solbu D, Bergh CH.
    Transplantation; 2010 Apr 15; 89(7):864-72. PubMed ID: 20061999
    [Abstract] [Full Text] [Related]

  • 12. mTOR inhibitor-associated proteinuria in kidney transplant recipients.
    Diekmann F, Andrés A, Oppenheimer F.
    Transplant Rev (Orlando); 2012 Jan 15; 26(1):27-9. PubMed ID: 22137729
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Conversion to a proliferation signal inhibitor in a patient with coronary artery disease--a case report.
    Sparacino V, Calabrese S.
    Nephrol Dial Transplant; 2006 Jul 15; 21 Suppl 3():iii34-7. PubMed ID: 16815856
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Recurrent non-melanoma skin cancer: remission of field cancerization after conversion from calcineurin inhibitor- to proliferation signal inhibitor-based immunosuppression in a cardiac transplant recipient.
    Signorell J, Hunziker T, Martinelli M, Koestner SC, Mohacsi PJ.
    Transplant Proc; 2010 Nov 15; 42(9):3871-5. PubMed ID: 21094874
    [Abstract] [Full Text] [Related]

  • 19. Renal function in children with heart transplantation after switching to CNI-free immunosuppression with everolimus.
    Behnke-Hall K, Bauer J, Thul J, Akintuerk H, Reitz K, Bauer A, Schranz D.
    Pediatr Transplant; 2011 Dec 15; 15(8):784-9. PubMed ID: 21883744
    [Abstract] [Full Text] [Related]

  • 20. [Replacing calcineurin inhibitors with proliferation signal inhibitors after kidney transplantation: indications, results, and disadvantages].
    Audard V.
    Nephrol Ther; 2009 Dec 15; 5 Suppl 6():S395-9. PubMed ID: 20129452
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.